Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. The Company’s pipeline is also highlighted by KO-539, a potent and selective inhibitor of the menin-KMT2A(MLL) protein-protein interaction currently in a Phase 1/2A clinical trial, KOMET-001, in patients with relapsed/refractory acute myeloid leukemia.
Location: United States, Massachusetts, Boston
Total raised: $60M
Investors 5
| Date | Name | Website |
| - | PFM Health... | pfmhealths... |
| - | Foresite C... | foresiteca... |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | Avoro Capi... | avorocapit... |
| - | EcoR1 Capi... | ecor1cap.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.03.2015 | - | $60M | - |
Mentions in press and media 8
| Date | Title | Description |
| 18.08.2024 | Two Bear Capital Appoints Five Key Executives | Two Bear Capital, a VC firm investing in life sciences and technology disruptors, announced the appointment of five key executives, expanding its team of experts during a period of rapid growth for the venture capital firm. These appointmen... |
| 06.03.2024 | Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma | - |
| 30.01.2024 | How an immunological Trojan horse could treat disease | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with some breathlessly anticipated news from Vertex Pharmaceuticals, an exit int... |
| 14.06.2023 | Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants | - |
| 03.11.2022 | Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million | - |
| 13.07.2017 | Merck KGaA life sciences reorg will claim 200 jobs; Tesaro shares sink on new report discounting buyout talk | → Merck KGaA is winnowing out 200 jobs over the next five years as it reorganizes its European life sciences business. The company is consolidating the manual filling and distribution of non-regulated laborator... |
| 12.03.2015 | Kura Oncology Finds $60M For Cancer Treatments | La Jolla-based Kura Oncology, a biopharmaceuticals startup focusing on treatments for solid tumors and blood cancers, has raised $60M in a private placement. The company said the funding came from EcoR1 Capital, along with Fidelity Manageme... |
| 12.03.2015 | Kura Oncology Raises $60M in Funding | Kura Oncology Inc., a La Jolla, California-based biopharmaceutical company focused on treating solid tumors and blood cancers, raised $60m in funding. The round was led by EcoR1 Capital with participation from Fidelity Management & Rese... |